Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
allogenic immunotherapy based on natural killer cells adoptive transfer-Centre Hospitalier Universitaire de Besancon-gastrointestinal cancer (metastatic)
- Development stage
- Unknown
- Lead developer
- CHU de Besançon
- Modality
- Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, Small Molecules, Cytokines & Interferons → Recombinant Proteins and Enzymes, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intra-arterial
01
Overview
This experimental immunotherapy protocol, developed by the Centre Hospitalier Universitaire de Besançon, involves the adoptive transfer of allogeneic, haploidentical natural killer (NK) cells in combination with the monoclonal antibody cetuximab. Specifically designed for patients with EGFR-positive metastatic gastrointestinal cancers and liver metastases, the NK cells are administered via hepatic intraarterial infusion to achieve high local concentrations in the liver. The treatment regimen includes lymphodepleting conditioning with cyclophosphamide and fludarabine, followed by the NK cell infusion, weekly cetuximab to facilitate antibody-dependent cellular cytotoxicity (ADCC) against tumor cells, and interleukin-2 (IL-2) to support the survival, expansion, and activation of the transferred NK cells.
- Other names
- allogenic immunotherapy based on natural killer cells adoptive transferNK cell immunotherapy with cetuximabhaploidentical NK cell therapy
02
Targets
EGFR T790M (Epidermal growth factor receptor T790M mutant)IL-2R (Interleukin-2/interleukin-15 receptor complex)FcγRIIIa (Low affinity immunoglobulin gamma Fc region receptor III-A)
Beyond the preview
Go deeper on allogenic immunotherapy based on natural killer cells adoptive transfer-Centre Hospitalier Universitaire de Besancon-gastrointestinal cancer (metastatic).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on allogenic immunotherapy based on natural killer cells adoptive transfer-Centre Hospitalier Universitaire de Besancon-gastrointestinal cancer (metastatic).